Severe combined immunodeficiencies and related disorders

Area of Science:

• Immunology
• Genetics
• Pediatrics

Background:

• Severe combined immunodeficiencies (SCIDs) are rare, monogenic diseases.
• SCIDs cause a profound block in T lymphocyte development, leading to severe infections and early death without intervention.
• Atypical SCIDs or combined immunodeficiencies involve profound, incomplete T cell deficiencies.

Purpose of the Study:

• To review the pathophysiology, diagnosis, and treatment of SCIDs.
• To highlight advances in newborn screening and therapeutic options.
• To discuss future challenges in managing long-term outcomes for SCID patients.

Main Methods:

• Review of scientific literature on SCID pathophysiology and treatment.
• Analysis of diagnostic advancements, including newborn screening.
• Evaluation of therapeutic outcomes, including allogeneic hematopoietic stem cell transplantation and gene therapy.

Main Results:

• Identification of numerous molecular defects causing SCIDs and related immunodeficiencies.
• Significant improvements in SCID care due to early diagnosis and newborn screening.
• Gene therapy emerging as an effective treatment option with future potential.

Conclusions:

• Early and precise diagnosis is crucial for improving SCID patient outcomes.
• Allogeneic hematopoietic stem cell transplantation and gene therapy are effective treatments.
• Long-term outcome assessment, including immune restoration and non-hematopoietic manifestations, remains a key challenge.